Letter to the Editor: Switching from vedolizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study
PMID: 38311530
Source: Dig Liver Dis
Publication date:
2024-02-04
Year:
2024
Abstract
NULL